about
Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the FateCOX-2 Inhibitors and Gastric CancerBreast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts.Multiple roles of dihomo-γ-linolenic acid against proliferation diseases.Antitumor Activity of Cytotoxic Cyclooxygenase-2 InhibitorsCo-expressed differentially expressed genes and long non-coding RNAs involved in the celecoxib treatment of gastric cancer: An RNA sequencing analysis.Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinomaTargeting the LKB1 tumor suppressor.Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: a meta-analysis.Innate Immunity Post-Hematopoietic Stem Cell Transplantation: Focus on EpigeneticsA Nile blue based infrared fluorescent probe: imaging tumors that over-express cyclooxygenase-2.miR-137 effects on gastric carcinogenesis are mediated by targeting Cox-2-activated PI3K/AKT signaling pathway.GEC-derived SFRP5 inhibits Wnt5a-induced macrophage chemotaxis and activationReduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer.Anti-cancer effect of low dose of celecoxib may be associated with lnc-SCD-1:13 and lnc-PTMS-1:3 but not COX-2 in NCI-N87 cells.COX-2, TFF1, and Src define better prognosis in young patients with gastric cancer.Protein predictive signatures for lymph node metastasis of gastric cancer.Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients.
P2860
Q26777205-773CA880-F6B0-44A9-B6EB-E1FAB538A4D7Q27692701-F7A553AA-E911-41E3-9DF8-770511B48A47Q33566771-49CA43F4-0E6D-4378-B05E-367C668D2401Q35809033-3C6D27EF-5135-4297-9CE2-D2AF717F1D34Q36121287-812901A9-1A6E-463A-821A-606F678A7C96Q36152244-C4A48C85-6F9C-4A87-AE1C-75579ED18133Q37269094-A710B504-16B7-4807-86D3-5643E57A22F6Q37506032-76CFDED8-45A2-4B40-B802-102D99A7B21CQ38157778-711DFC36-64DB-4103-B87A-E241CD5D7D61Q38680909-5E411741-3B27-4828-94FA-32BD81E738EDQ38937824-533CDFF7-5532-4CD9-938E-A1B12440667AQ38971368-2B9FB56B-8931-4DC3-9FD8-1303972876EBQ39035083-FAB751B9-1FD3-4A3B-8977-0EC5C1FDA1E8Q39487878-9E36FDC0-A99E-4628-A34B-34B98DC78E39Q41143541-F41C8B4F-8D77-4D11-901F-8C16FE592451Q42269526-9BDBF611-4218-460B-9C1E-55F26B514708Q46429361-099F2E02-93EA-496D-B6BF-6EA0642B34DFQ51141555-60DEEECE-F5A9-4201-A2FE-A0BE6104C27B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cyclooxygenase-2 and gastric cancer.
@en
Cyclooxygenase-2 and gastric cancer.
@nl
type
label
Cyclooxygenase-2 and gastric cancer.
@en
Cyclooxygenase-2 and gastric cancer.
@nl
prefLabel
Cyclooxygenase-2 and gastric cancer.
@en
Cyclooxygenase-2 and gastric cancer.
@nl
P2093
P2860
P1476
Cyclooxygenase-2 and gastric cancer.
@en
P2093
Alexandra Thiel
Ari Ristimäki
Johanna Mrena
P2860
P2888
P304
P356
10.1007/S10555-011-9312-1
P577
2011-12-01T00:00:00Z